NeoGenomics, Inc. (NEO)
Largest Insider Buys in Sector
NEO Stock Price History Chart
NEO Stock Performance
About NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence …
Insider Activity of NeoGenomics, Inc.
Over the last 12 months, insiders at NeoGenomics, Inc. have bought $0 and sold $218,581 worth of NeoGenomics, Inc. stock.
On average, over the past 5 years, insiders at NeoGenomics, Inc. have bought $520,710 and sold $29.88M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 17,000 shares for transaction amount of $520,710 was made by Mallon Mark (Chief Executive Officer) on 2021‑12‑06.
List of Insider Buy and Sell Transactions, NeoGenomics, Inc.
| 2024-08-15 | Sale | General Counsel | 1,040 0.0008% | $16.05 | $16,695 | 0.00% | ||
| 2024-05-15 | Sale | General Counsel | 1,049 0.0009% | $15.74 | $16,511 | -4.07% | ||
| 2024-03-04 | Sale | director | 6,112 0.0048% | $15.97 | $97,579 | -8.03% | ||
| 2024-02-15 | Sale | General Counsel | 2,587 0.002% | $14.96 | $38,713 | -0.60% | ||
| 2023-11-17 | Sale | General Counsel | 2,669 0.002% | $18.39 | $49,083 | -20.54% | ||
| 2022-03-07 | Sale | Chief Financial Officer | 3,209 0.0026% | $18.29 | $58,693 | -43.84% | ||
| 2021-12-21 | Sale | Chief Financial Officer | 1,846 0.0015% | $35.00 | $64,610 | -70.51% | ||
| 2021-12-06 | Chief Executive Officer | 17,000 0.0137% | $30.63 | $520,710 | -67.38% | |||
| 2021-11-26 | Sale | Chief Strategy Officer | 33,334 0.0279% | $36.85 | $1.23M | -71.51% | ||
| 2021-11-24 | Sale | Chief Strategy Officer | 33,333 0.0272% | $36.84 | $1.23M | -72.23% | ||
| 2021-11-24 | Sale | President, Informatics | 25,000 0.0206% | $37.13 | $928,250 | -72.23% | ||
| 2021-11-23 | Sale | Chief Strategy Officer | 33,333 0.0277% | $37.19 | $1.24M | -71.94% | ||
| 2021-06-08 | Sale | director | 20,734 0.0173% | $41.46 | $859,632 | -18.52% | ||
| 2021-06-03 | Sale | President, Pharma Services | 31,107 0.0263% | $40.11 | $1.25M | -13.21% | ||
| 2021-06-02 | Sale | President, Pharma Services | 169,230 0.1436% | $40.39 | $6.84M | -12.99% | ||
| 2021-05-25 | Sale | President, Clinical Services | 130,604 0.1108% | $39.31 | $5.13M | -3.93% | ||
| 2020-12-14 | Sale | director | 25,000 0.0229% | $51.67 | $1.29M | -11.37% | ||
| 2020-12-14 | Sale | Chief Medical Officer | 20,200 0.0183% | $51.06 | $1.03M | -11.37% | ||
| 2020-12-11 | Sale | director | 25,000 0.0229% | $50.52 | $1.26M | -8.99% | ||
| 2020-12-11 | Sale | VP and Chief Culture Officer | 15,000 0.0136% | $49.99 | $749,850 | -8.99% |
Insider Historical Profitability
| TETRAULT LYNN A. | director | 50062 0.0391% | $15.26 | 2 | 3 | +1.24% |
| KINDERHOOK, LP | 10 percent owner | 4848334 3.7831% | $15.26 | 5 | 0 | +67.31% |
| VAN OORT DOUGLAS M | Chairman and CEO | 2422790 1.8905% | $15.26 | 10 | 8 | +14.04% |
| CARDOZA GEORGE | President, Pharma Services | 176772 0.1379% | $15.26 | 2 | 12 | +53.1% |
| SHOVLIN ROBERT J. | President, Clinical Services | 150101 0.1171% | $15.26 | 1 | 11 | +4.82% |
Institutional Investor Ownership
| BlackRock | $312.06M | 15.54 | 19.85M | -0.65% | -$2.05M | 0.01 | |
| The Vanguard Group | $223.4M | 11.13 | 14.21M | +0.29% | +$650,084.88 | <0.01 | |
| Brown Advisory | $152.01M | 7.57 | 9.67M | +0.27% | +$411,486.72 | 0.2 | |
| T Rowe Price Investment Management Inc | $107.8M | 5.37 | 6.86M | +7.44% | +$7.47M | 0.07 | |
| Janus Henderson | $98.73M | 4.92 | 6.28M | -1.07% | -$1.06M | 0.05 |